



**FOR IMMEDIATE RELEASE**  
Wednesday, October 29, 2003

**CONTACT:** Floyd E. Bloom, M.D.  
Founding Chief Executive Officer  
(858) 677-0466

## **NEUROME Announces Discovery Research Collaboration with WYETH**

**LA JOLLA, CA, October 29, 2003** - Neurome, Inc., a privately held biotech company focused on molecular and cellular neuropathology, announced today that it has entered into a research agreement with Wyeth (NYSE:WYE), in which Neurome will employ its proprietary technologies and expertise in quantitative neuropathology to assist Wyeth in its Discovery Research efforts involving treatment of Central Nervous System (CNS) disorders. Under the terms of the multi-year agreement, Neurome will receive research funding from Wyeth.

In this collaboration, Neurome and Wyeth will work together to investigate a number of aspects of CNS disease, beginning with the comprehensive evaluation and morphological analysis of one of Wyeth's transgenic animal models of Alzheimer's disease used to evaluate selected preclinical compounds. The collaboration will leverage Neurome's extensive experience with animal models of CNS diseases and proprietary technologies (the Neurome Technologies) to derive quantitative 3-D information, including volumetric analysis, on these animals.

"We are delighted that Wyeth has chosen to work with Neurome," said Floyd E. Bloom, M.D., Founding Chief Executive Officer and Chairman of the Board of Neurome and Chairman of the Department of Neuropharmacology at The Scripps Research Institute. "The Neurome Technologies and tools created at Neurome were designed to provide accelerated and highly focused goal-directed methods for drug development and research. We look forward to a productive relationship that will accelerate Wyeth's Research's efforts in Neuroscience."

### **About Neurome**

Neurome, Inc. performs contract brain research for pharmaceutical and biotechnology companies while at the same time pursuing its own in-house and collaborative research protocols. The data collected from these efforts will populate an evolving, comprehensive database available by subscription and useful on a broad level for analyses of mouse models of brain function and disease. Neurome develops standardized, quantitative databases that accurately depict and integrate

gene expression patterns in the three-dimensional context of the brain's structures, circuits, and cells, and deploys these databases in primary research directed toward the discovery and development of gene targets for enhancement of brain function and treatment of brain-based disease. In this regard, the application of the Neurome Technologies will provide rigorous, quantitative data that are optimally suited to the measurement of subtle cell-type specific shifts in gene expression, as well as progression and prevention of degenerative events affecting specific cell classes and brain regions. For more information, please visit Neurome's website at [www.neurome.com](http://www.neurome.com).

Except for historical statements, this press release contains forward-looking statements involving significant risks and uncertainties, and a number of factors, both foreseen and unforeseen, could cause actual results to differ materially from Neurome's current expectations. Forward-looking statements include those which express a plan, belief, expectation, estimation, anticipation, intent, contingency, future development or similar expression. Readers are cautioned that forward-looking statements are not guarantees of future performance and that undue reliance should not be placed on such statements. Forward-looking statements speak only as of the dates on which they were made. Neurome undertakes no obligation to publicly update or revise any forward-looking statements or to make any other forward-looking statements, whether as a result of new information, future events or otherwise unless required to do so by the securities laws.

###